Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...